Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab.

Journal of Clinical Oncology · 10 Nov 2026 · Letter

Li, Shao + more

The abstract is read at the publisher; the summary is JClub's.

There's no AI summary of this paper here yet.

Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.

Journals this month

bioRxiv6399
medRxiv1720
PNAS508
Sci Adv379
JAMA333
Cell Rep302
Environ Pollution234
Environ Res217
BMJ214
Nat Commun190
Science185
NEJM170
Plant Cell Environ169
New Phytol157
NAR157
EHJ154
Lancet151
Curr Biol129

All journals →

Topics moving, week to 13 Nov 2026

Single-cell and spatial transcriptomics8
CAR-T cell therapy research7
CRISPR and Genetic Engineering6
Lung Cancer Treatments and Mutations4
Pancreatic and Hepatic Oncology Research4
Gut microbiota and health4
Lipoproteins and Cardiovascular Health3
Genomics and Phylogenetic Studies3
Inflammatory Bowel Disease3
RNA and protein synthesis mechanisms3

All topics →

By field

General Science & Medicine19
Clinical Medicine18
Cell & Molecular Biology21
Immunology & Inflammation5
Neuroscience7
Genomics & Bioinformatics21
Microbiology & Mycology23
Oncology9
Protected Cropping & Horticultural Science4
Plant Physiology & Photobiology12
Student Research1

All journals by field →

Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab.

Browse JClub